DoD Breast Cancer Breakthrough Award Levels 1 and 2
Department of Defense
Dept. of the Army — USAMRAA
I. FUNDING OPPORTUNITY DESCRIPTION
A. Program Description
Applications to the Fiscal Year 2015 (FY15) Breast Cancer Research Program (BCRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation appropriation. The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP). The BCRP was initiated in fiscal year 1992 (FY92) to support innovative, high-impact research focused on ending breast cancer. Appropriations for the BCRP from FY92 through FY14 totaled $3 billion. The FY15 appropriation is $120 million (M).
The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.
B. Breast Cancer Landscape
The BCRP has prepared a brief overview of the breast cancer landscape that describes what is currently known about incidence, death, recurrence, metastatic disease, risk factors, and treatments. This overview covers the most pertinent topics that are consistent with the BCRP’s vision of ending breast cancer. Applicants are strongly urged to read and consider the landscape before preparing their applications. The landscape may be found at http://cdmrp.army.mil/bcrp/pdfs/bc_landscape.pdf.
|Posted Date:||Aug 25, 2015|
|Creation Date:||Aug 25, 2015|
|Original Closing Date for Applications:||Dec 2, 2015|
|Current Closing Date for Applications:||Dec 2, 2015|
|Archive Date:||Jan 1, 2016|
|Estimated Total Program Funding:||$25,000,000|
Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
|Additional Information on Eligibility:|
|Agency Name:||Dept. of the Army — USAMRAA|
|Description:||The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. An additional funding level, Funding Level 3, is available under a different Program Announcement (W81XWH-15-BCRP-BREAKTHROUGH2_FL3). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. • Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, called the Initiating PI and the Partnering PI, each of whom will receive a separate award. The Initiating and Partnering PIs have different submission requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions. Applications submitted by a mentor and his/her current postdoctoral fellow or junior investigator as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option.|